Category Archives: Alternative Medicine

The Global Complementary and Alternative Medicine Market report dissects the complex fragments of the market in an easy to read manner. This report covers drivers, restraints, challenges, and threats in the Complementary and Alternative Medicine market to understand the overall scope of the market in a detailed yet concise manner. Additionally, the market report covers the top-winning strategies implemented by major industry players and technological advancements that steers the growth of the market.

Key Players Landscape in the Complementary and Alternative Medicine Report

Columbia NutritionalHerb PharmHerbal HillsHelio USADeepure PlusNordic NaturalsPure encapsulationsIyengar Yoga InstituteJohn Schumachers Unity Woods Yoga CenterYoga TreeThe Healing CompanyQuantum Touch

Note: Additional or any specific company of the market can be added in the list at no extra cost.

Here below are some of the details that are included in the competitive landscape part of the market report:

This market research report enlists the governments and regulations that can provide remunerative opportunities and even create pitfalls for the Complementary and Alternative Medicine market. The report confers details on the supply & demand scenario in the market while covering details about the product pricing factors, trends, and profit margins that helps a business/company to make crucial business decisions such as engaging in creative strategies, product development, mergers, collaborations, partnerships, and agreements to expand the market share of the company.

Get Free Exclusive Sample report @ https://dataintelo.com/request-sample/?reportId=217839

An Episode of Impact of COVID-19 Pandemic in the Complementary and Alternative Medicine Market

The COVID-19 pandemic had disrupted the global economy. This is due to the fact that the government bodies had imposed lockdown on commercial and industrial spaces. However, the market is anticipated to recover soon and is anticipated to reach the pre-COVID level by the end of 2021 if no further lockdown is imposed across the globe.

In this chapter of the report, DataIntelo has provided in-depth insights on the impact of COVID-19 on the market. This chapter covers the long-term challenges ought to be faced due to the pandemic while highlights the explored opportunities that benefited the industry players globally. The market research report confers details about the strategies implemented by industry players to survive the pandemic. Meanwhile, it also provides details on the creative strategies that companies implemented to benefit out of pandemic. Furthermore, it lays out information about the technological advancements that were carried out during the pandemic to combat the situation.

What are the prime fragments of the market report?

The Complementary and Alternative Medicine report can be segmented into products, applications, and regions. Here below are the details that are going to get covered in the report:

Products

BotanicalsAcupunctureMind, Body, and YogaMagnetic Intervention

Applications

Direct ContactE-trainingDistance Correspondence

Regions

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America

Note: A country of your own choice can be added to the list at no extra cost. If more than one country needs to be added, the research quote varies accordingly.

Buy the complete report in PDF format: https://dataintelo.com/checkout/?reportId=217839

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Complementary and Alternative Medicine Market Overview

Global Complementary and Alternative Medicine Market Analysis and Forecast by Type

Global Complementary and Alternative Medicine Market Analysis and Forecast by Application

Global Complementary and Alternative Medicine Market Analysis and Forecast by Sales Channel

Global Complementary and Alternative Medicine Market Analysis and Forecast by Region

North America Complementary and Alternative Medicine Market Analysis and Forecast

Latin America Complementary and Alternative Medicine Market Analysis and Forecast

Europe Complementary and Alternative Medicine Market Analysis and Forecast

Asia Pacific Complementary and Alternative Medicine Market Analysis and Forecast

Asia Pacific Complementary and Alternative Medicine Market Size and Volume Forecast by Application

Middle East & Africa Complementary and Alternative Medicine Market Analysis and Forecast

Competition Landscape

If you have any doubt about the report, please feel free to contact us @ https://dataintelo.com/enquiry-before-buying/?reportId=217839

About DataIntelo

DataIntelo has extensive experience in the creation of tailored market research reports in several industry verticals. We cover in-depth market analysis which includes producing creative business strategies for the new entrants and the emerging players of the market. We take care that our every report goes through intensive primary, secondary research, interviews, and consumer surveys. Our company provides market threat analysis, market opportunity analysis, and deep insights into the current and market scenario.

To provide the utmost quality of the report, we invest in analysts that hold stellar experience in the business domain and have excellent analytical and communication skills. Our dedicated team goes through quarterly training which helps them to acknowledge the latest industry practices and to serve the clients with the foremost consumer experience.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 414 1393

Email:[emailprotected]

Website:https://dataintelo.com

Visit link:

Complementary and Alternative Medicine Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- Columbia Nutritional, Herb...

The World Forum for Ethics in Business (WFEB) is gearing up for the mega virtual event that is scheduled for April 7. Ahead of it, the public interest foundation held a live session on "Integrated Medicine: New Paradigm of Healing". In the 30-minute-long conversation, Dr Prachi Garodia, an internal medicine doctor and a plant-based Ayurvedic chef shared her perspective on how integrative medicine is paving the way to optimal health and wellness.

Commencing the session with her own introduction, Dr Garodia said that she was currently serving the Veteran's Health Administration in the US and has been working on a "radical transformation of healthcare" from a disease-based model to a more patient-centred model. "We were trained to suppress the symptoms," she said, talking about the modern medicine. However, the real focus, according to her, should be on healing and lifestyle changes.

When asked about her take on the paradigm of integrated medicine or "medicine of future", Dr Garodia replied, "Once we look at the dismal state of affairs that we are in, we know that whatever we have right now is not working". Speaking further, she highlighted that there have been pandemics and epidemics of chronic-irreversible disease going up in the recent past. Talking about a solution to the same, she said that a more "proactive" and "right" kind of treatment should have been the basic approach to start with.

"There would have been a much healthier, happier and more productive population had the right approach be followed. Additionally, there also had been a lesser burnout in the field of healthcare. Integrated medicine provides a good solution to our healthcare system," said Dr Garodia.

She also clarified that there have been a lot of names going on like holistic medicine, alternate medicine etc, but all are different. Describing integrated medicine, Dr Garodia said that it functions like conventional medicine while also integrating alternative or traditional treatment practices. "The best way to go ahead is adopting certain traditions which have been practised for thousands of years," she said.

When asked about applying integrated medicine to daily life, the doctor asserted that she has had tons of stories about healing. She then narrated the case of a paralysed overweight patient who was healed with only little change in diet and lifestyle. She explained that health is not just absence of disease but to find "higher purpose and meaning in life". She added that "most of the time we are looking for outside, while it is inside and we have the power to change that".

Commenting on the current scenario and how integrated medicine could be applied to the COVID-19 pandemic, she asserted that the treatment, its skillset and modalities could be followed in multiple ways. "First learn how to live everyday life in harmony with the cycle of nature She concluded that apart from eating and sleeping correctly, improving ones resilience, paying gratitude could also help in improving mind, body and emotional functioning. "It would not only improve our relationship with oneself but also how we perform at life and communicate with family, friends, society and in fact the whole planet," she said.

Read more:

Medicine of future: WFEB session on integrative medicine being new paradigm in healing - Republic TV

Early studies into the beneficial effects of mescaline have indicated that it may show some promise in treating depression, anxiety, PTSD, and addiction all conditions which cost the global economy billions of dollars each day. It therefore has the potential to carve out a significant share of the $70bn global mental health market.

However, the life sciences companies spearheading the resurgence in psychedelics have not yet given mescaline the attention it deserves. They have poured their resources into psilocybin cultivation and research, while generally overlooking mescaline arguably the worlds oldest psychedelic.

That situation is now set to change. XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTCQB: XPHYF), a pioneering bioscience company based in Vancouver, Canada, has added the production of pharmaceutical-grade mescaline to its psychedelic medicine programmes.

The company plans to develop industrial-scale pharmaceutical-grade production processes for the wholesale market and for incorporation into the companys thin film drug delivery platforms. XPhyto says that mescaline has been anecdotally recognised as a relatively safe psychedelic drug and that it has displayed particular promise for the treatment of addiction and depression.

We see a significant market opportunity in the production of pharmaceutical mescaline and the standardisation of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use, says XPhyto Chief Executive Officer Hugh Rogers.

XPhytos early adoption of mescaline as a medicinal product has made it a leading contender in the race to bring the next potential blockbuster psychedelic drug to market.

The small cap markets, dealing with companies which have market capitalisations between $300m and $2bn, have been flooded with intriguing psychedelics stocks over the past couple of years. This sector gained significant momentum in 2020: for example, Mind Medicine Inc saw its share price increase 864% last year. The share price of Numinus Wellness increased 555% in 2020, while Red Light Hollands stock increased 300%. Investors in several other psychedelics stocks saw their money double or triple last year, and it appears to be an exciting potential growth area.

As previously mentioned, the global mental health treatment market is worth an estimated US $70bn a year. Depression is perhaps the most urgent concern for healthcare professionals and economic leaders alike. A recent World Health Organization (WHO)-led study estimated that depression and anxiety disorders cost the global economy $1tn each year in lost productivity. More than 16 million people in the United States and 264 million people worldwide suffer from depression, according to the WHO.

Allied Market Research expects the antidepressant drugs market to reach $16bn by 2023. However, between 10% and 30% of patients fail to respond to antidepressants, so the need for a new weapon to combat this crippling condition is clear as numbers continue to rise.

The application of cannabis as an alternative treatment to antidepressants does not appear to have been as effective as anticipated. In fact, the traditional antidepressant market has continued to grow despite the increasingly widespread legalisation of medical cannabis over the past several years the drug has been legalised for medical use since 2001 in Canada; 2008 in Austria; 2013 in Italy; 2016 in Australia; 2017 in Germany and Mexico; 2018 in the UK; and 2019 in Ireland, among others.

Some advocates have contended that psychedelics have far greater potential to disrupt the antidepressant market than cannabis. The US Food and Drug Administration (FDA) considers psychedelics to be a breakthrough therapy for treating severe depression, causing the leading companies in this nascent sector to enjoy soaring stock market valuations as interest in its potential grows.

It is interesting to see XPhyto pushing boundaries by looking past the shroom boom and exploring the potential of mescaline. In Europe, the company is already involved in the development of a proprietary biotechnology process for the industrial manufacture of pharmaceutical-grade psilocybin, but it has decided to cast its net wider in a bid to be a major player in the psychedelic market.

The real money in psychedelics will be made from FDA-approved drugs which can be proven to treat depression, addiction and other mental health conditions. A landmark moment came in March 2019, when the FDA approved the ketamine derivative esketamine. Pharmaceutical giant Johnson & Johnson now sells esketamine in the form of a nasal spray used to treat depression.

Advocates of psychedelics hope that developments like this will pave the way for a number of other substances to break into the mainstream. Market intelligence firm Data Bridge Market Research forecasts that the psychedelic pharmaceuticals market could grow to almost $7bn by 2027, and mescaline could play a key role in this growth.

Research into the psychotherapeutic potential of mescaline is understandably limited right now, but several studies suggest it could successfully treat mental health conditions. It is thought to increase blood flow and activity in the prefrontal cortex: low activity in this area is linked to depression and anxiety, leading some proponents to hypothesise that microdosing mescaline could alleviate those conditions.

Researchers at the University of Alabama found that the use of classic psychedelic drugs, including mescaline, could have the potential to curb suicidal thoughts. Another study found that mescaline is associated with reduced symptoms of agoraphobia, which could theoretically be a growing concern as the world emerges from COVID-19 lockdowns. Elsewhere, a researcher at Harvard University has identified anecdotal evidence that mescaline use may lead to reduced rates of alcoholism and drug abuse among Native American demographics.

Mescaline is found in the San Pedro cactus as well as several other species found in the Andes, Mexico and the Southwestern United States. Archaeological evidence shows that its use goes back at least 5,000 years. It was legal in the United States until 1970, when then-President Richard Nixon launched a crackdown on psychedelics; but it is now making a comeback within selected academic circles.

However, to date very few companies have recognised the commercial potential of mescaline, giving XPhyto the opportunity to secure first-mover advantage assuming that mescaline attains FDA approval and is rescheduled by the DEA.

Mescaline remains a Schedule 1 drug in the United States, but it is legal in certain religious ceremonies registered by the Native American Church. There is also a substantial black market for mescaline, so it might make sense for the government to legalise, regulate and tax it.

The societal cost of depression and anxiety is growing increasingly difficult to ignore, and there is a clear motivation for governments to consider innovative solutions such as mescaline.

Researchers at prestigious universities like Johns Hopkins University, Imperial College London and Kings College London have provided the psychedelics sector with a much-needed injection of credibility. Mescaline may no longer be viewed as a counterculture movement. This is the sharp end of the race to combat mental health conditions, led by hard-nosed scientists and pioneering psychotherapists.

Politicians are also growing increasingly open towards psychedelics. Just last month, US Senator Scott Wiener (D-San Francisco) introduced Senate Bill 519, which seeks to legalise mescaline, along with ketamine, psilocybin, LSD and DMT, in California. Health Canada has given doctors and therapists permission to use psilocybin as they develop therapies, suggesting a paradigm shift in governments attitudes towards psychedelics; and this trend is highly likely to accelerate in the months and years to come.

XPhyto describes itself as a bioscience accelerator. It operates a range of research and development projects in both Canada and Germany. The company has expertise in using sublingual and transdermal therapeutics to deliver extremely precise doses, which could prove invaluable for microdosing mescaline and other psychedelics.

Professor Raimar Lbenberg is overseeing XPhytos focus on turning promising psychedelics into therapeutic pharmaceutical drugs. He is the founder of the Drug Development and Innovation Centre at the University of Alberta and the former president of the Canadian Society for Pharmaceutical Sciences. Lbenberg has the necessary Health Canada licences to conduct this research, making him one of the few scientists in North America to enjoy such status.

XPhyto intends to first produce psychedelic active pharmaceutical ingredients, which can then be incorporated into our novel sublingual and transdermal delivery systems, he says. This is our competitive advantage, from production of API to drug formulation to clinical validation.

Knox Henderson XPhyto Therapeutics +1 604 551 2360khenderson@xphyto.com http://www.xphyto.com

This article is from issue 17 ofHealth Europa.Clickhereto get your free subscription today

Recommended Related Articles

Link:

XPhyto: Is mescaline the next big mood-modifying medicine? - Health Europa

AYUSH and Alternative Medicine Market 2021-2026:

The Global AYUSH and Alternative Medicine market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2015-2026. On the basis of historical data, AYUSH and Alternative Medicine market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the market AYUSH and Alternative Medicine industry is likely to appear as a commendable platform for emerging AYUSH and Alternative Medicine market investors.

The complete value chain and downstream and upstream essentials are scrutinized in this report. Essential trends like globalization, growth progress boost fragmentation regulation & ecological concerns. This Market report covers technical data, manufacturing plants analysis, and raw material sources analysis of AYUSH and Alternative Medicine Industry as well as explains which product has the highest penetration, their profit margins, and R & D status. The report makes future projections based on the analysis of the subdivision of the market which includes the global market size by product category, end-user application, and various regions.

Get Sample Report: https://www.marketresearchupdate.com/sample/157953

This AYUSH and Alternative Medicine Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better.

Topmost Leading Manufacturer Covered in this report:

Baidyanath, Himalya Herbals, Ganga Pharmaceuticals, Patanjali, Hamdard

Product Segment Analysis:

Ayurvedic Medicines Herbal Medicines Aroma Therapy Homeopathy Reflexology Others

Application Segment Analysis:

Women Men Kids

Get Discount @ https://www.marketresearchupdate.com/discount/157953

Regional Analysis For AYUSH and Alternative MedicineMarket

North America(the United States, Canada, and Mexico)

Europe(Germany, France, UK, Russia, and Italy)

Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)

South America(Brazil, Argentina, Colombia, etc.)

The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

The objectives of the report are:

To analyze and forecast the market size of AYUSH and Alternative MedicineIndustry in theglobal market.

To study the global key players, SWOT analysis, value and global market share for leading players.

To determine, explain and forecast the market by type, end use, and region.

To analyze the market potential and advantage, opportunity and challenge, restraints and risks of global key regions.

To find out significant trends and factors driving or restraining the market growth.

To analyze the opportunities in the market for stakeholders by identifying the high growth segments.

To critically analyze each submarket in terms of individual growth trend and their contribution to the market.

To understand competitive developments such as agreements, expansions, new product launches, and possessions in the market.

To strategically outline the key players and comprehensively analyze their growth strategies.

View Full Report @ https://www.marketresearchupdate.com/industry-growth/ayush-and-alternative-medicine-market-size-analysis-by-application-157953

At last, the study gives out details about the major challenges that are going to impact market growth. They also report provides comprehensive details about the business opportunities to key stakeholders to grow their business and raise revenues in the precise verticals. The report will aid the companys existing or intend to join in this market to analyze the various aspects of this domain before investing or expanding their business in the AYUSH and Alternative Medicine markets.

Contact Us:

[emailprotected]

Continue reading here:

AYUSH and Alternative Medicine Market 2021: Current and Future Trends SoccerNurds - SoccerNurds

From curing herpes to treating diabetes in a new way, their innovations might one day treat some of the worlds most prevalent health problems. This years two finalists in STAT Madness, a bracket-style competition that showcases cutting-edge research across the biomedical sciences, harnessed new approaches to devise possible therapies that could help millions of people with all-too-common maladies.

One team, from the Fred Hutchinson Cancer Research Center, developed a gene-editing technique with the potential to effectively treat and even cure herpes. The other finalist, a group from the Massachusetts Institute of Technology and Brigham and Womens Hospital, devised a liquid solution that coats the small intestine with a temporary adhesive, a noninvasive technique with wide applications from efficient drug delivery to treating diabetes.

The competition was stiff, with well over 1 million votes cast during the month-long contest, blowing past last years record of almost 700,000 votes. In the end, both teams were declared winners. STAT editors made that decision in the interest of fairness, after identifying unusual voting patterns in the final round.

advertisement

Martine Aubert, Keith Jerome, and their colleagues at Fred Hutch tested a new method of gene therapy to treat herpes, improving on previous research done by Jerome. Using gene editing in mice, the researchers removed over 90% of the virus from the cells that it mainly infects, they reported in a paper published in Nature.

Jerome, a virologist and a professor at Fred Hutch and the University of Washington, said that after years of improving their gene editing approach, he was more thrilled than surprised about the promising results. Thats what we were going for, he said.

advertisement

Existing antiviral treatments for herpes typically address the infection temporarily, but latent virus still remains in the body, hiding in the peripheral nerves and periodically reactiving. Type 1 HSV usually causes cold sores around the mouth and lips; type 2 causes sores on the genitals. Herpes is incredibly common, affecting over two-thirds of people under age 50 worldwide. In their study, the researchers tested their treatment for the type 1 virus, but think it would also be effective for type 2.

In previous research, Aubert and Jerome had found that using a DNA-clipping enzyme called meganuclease, they could effectively target viral DNA in infected cells and damage the herpes virus. The enzymes used in the research were delivered to cells via a hollowed-out virus-like particle, called a viral vector. In the Nature study, the researchers also experimented with other gene-editing approaches, such as CRISPR/Cas9.

You can see some signs [CRISPR/Cas9] was working a bit, but the meganucleases were way, way better, said Jerome.

Several incremental improvements to the researchers original method enabled it to destroy almost all of the herpes virus in the peripheral nerve cells of mice, versus damaging 4% or less of the virus in the initial study.

In the new paper, the researchers hypothesized that if the technique works in humans, it would reduce viral shedding, which would make it harder to transmit the virus to others. In recent research, the researchers have further supported this idea using a mouse model Aubert developed that mimics viral shedding in humans. There were also some signs the technique could be improved upon even further, making it possible for it to effectively cure herpes.

There might be a tweak in there [that would explain] why some animals do better than others, said Aubert. For instance, some mice had no detectable disease at all.

It may take at least two-and-a-half years before the treatment enters human trials, said the researchers. They are planning to meet with the Food and Drug Administration by this summer to discuss what safety data they will need to collect before beginning a clinical trial. The researchers also said the technique might eventually be used to treat hepatitis B and HIV.

The other winning team was led by Junwei Li, a researcher at Brigham and Womens Hospital and a visiting scientist at MIT. The researchers developed a solution that, once inside the small intestine, undergoes a reaction and coats it with a temporary adhesive. Giovanni Traverso, an assistant professor of mechanical engineering at MIT and a gastroenterologist at Brigham and Womens Hospital, was the senior author of the study published in Science Translational Medicine.

Li said that using the coating to make drug delivery more efficient was one of the researchers main goals. Some drugs are metabolized quickly and largely go to waste before the body absorbs all the medication, he said. The coating would slow absorption of a drug, the researchers reasoned. The technology could not only make drugs more effective, said Li, but less expensive.

If we can increase this [absorption] by, for example five times, then you can lower the cost by five times, he said.

The solution is mainly made up of dopamine, which exists commonly in the body as a neurotransmitter. Once the dopamine enters the small intestine, it reacts with an enzyme called catalase in the intestinal lining. The reaction creates an adhesive polymer that temporarily coats the small intestine with a kind of molecular glue.The coating can stay there for 24 hours, which really maximizes the absorption window, Li said.

The small intestine is where most nutrients and also drugs are absorbed by the body, and also where the highest concentration of catalase is found. Because of this, the researchers found that the dopamine would not form a coating in areas they werent targeting, like the stomach. They tested the method in human and pig tissue in the lab, and also in live pigs, whose GI tracts are similar to those of humans. The solution was delivered into the pigs through a tube, but the researchers envision that patients would be able to drink it or swallow it as a pill or capsule.

In a series of experiments, the researchers investigated potential applications of the solution. In one, they found that the drug praziquantel, which treats the tropical, parasitic disease schistosomiasis, lasted far longer in pigs when combined with the solution. Praziquantel is normally taken three times a day, so using this technique could help decrease the dosing frequency.

Li and his team also found that in pigs, the solution created a more effective way to deliver the enzyme lactase to the digestive system, which could help lactose intolerant people, and that the coating decreased the speed at which glucose was absorbed, which could provide an alternative treatment for people with diabetes or obesity.

Safety testing of the solution in pigs and rats did not find any concerns.

The two teams emerged triumphant from nearly 130 submissions to STATs contest, out of which 64 entries were selected for the bracket. The submissions came from across the country and were selected based on scientific rigor, originality in their field, and potential impact.

Jerome is grateful for the large community who supported his teams research on social media, many of whom have herpes. He said he has also enjoyed looking at all the competitors research projects.

Ive learned a lot, he said.

Li said he enjoyed the engagement with his teams research and learning about other teams studies. While some of the students in the lab were quite invested in the competition, Li said he was never especially attached to winning. He sees the competition as being about exposing people to and engaging with exciting new research. He also said the competition was a welcome distraction and a way to connect with other researchers in a time of social isolation.

It was really fun, especially during quarantine, said Li.

Read the original post:

Research on therapies for herpes and diabetes win STAT Madness - STAT - STAT

Get Sample Report Buy Complete Report

Alternative and Complementary Medicine Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Alternative and Complementary Medicine Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=381626

Top Key Players Profiled in this report are:

Iyengar Yoga Institute, Columbia Nutritional Inc., Herbal Hills, Herb Pharm, John Schumachers Unity Woods Yoga Center, Yoga Tree, The Healing Company, Helio USA Inc., Deepure Plus, Quantum Touch Inc, Pure encapsulations, Nordic Naturals.

This report provides a detailed and analytical look at the various companies that are working to achieve a high market share in the global Alternative and Complementary Medicine market. Data is provided for the top and fastest growing segments. This report implements a balanced mix of primary and secondary research methodologies for analysis. Markets are categorized according to key criteria. To this end, the report includes a section dedicated to the company profile. This report will help you identify your needs, discover problem areas, discover better opportunities, and help all your organizations primary leadership processes. You can ensure the performance of your public relations efforts and monitor customer objections to stay one step ahead and limit losses.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Alternative and Complementary Medicine market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Alternative and Complementary Medicine market.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=381626

The cost analysis of the Global Alternative and Complementary Medicine Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Global Alternative and Complementary Medicine Market Segmentation:

Market Segmentation by Type: Botanicals, Acupuncture, Mind, Body, and Yoga, Magnetic Intervention.

Market Segmentation by Application: Direct Contact, E-training, Distance Correspondence.

Reasons for buying this report:

Table of Contents

Global Alternative and Complementary Medicine Market Research Report 2021

Chapter 1 Alternative and Complementary Medicine Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Alternative and Complementary Medicine Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=381626

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Go here to see the original:

Alternative and Complementary Medicine Market to Witness Rapid Growth by 2027 | Iyengar Yoga Institute, Columbia Nutritional Inc., Herbal Hills, Herb...

Dr Paul Chrisp, director of the Centre for Guidelines at NICE, said: We want this guideline to make a positive difference to people with chronic pain, and their families and carers.

It highlights that achieving an understanding of how pain is affecting a persons life and those around them and knowing what is important to the person is the first step in developing an effective care and support plan that recognises and treats a persons pain as valid and unique to them.

Pain that lasts for more than 3months is known as chronic or persistent pain. In the UK the prevalence of chronic pain is uncertain, but appears common, affecting perhaps one-third to one-half of the population. The prevalence of chronic primary pain is unknown but is estimated to be between 1 and 6% in England.

Chronic pain that is caused by an underlying condition (for example, osteoarthritis, rheumatoid arthritis, ulcerative colitis, endometriosis) is known as chronic secondary pain. Where the cause of the pain is unclear it is called chronic primary pain. Although the NICE guideline covers the assessment and development of a care and support plan for all types of chronic pain, it focuses on treatments for chronic primary pain. Pain management as part of palliative care is not covered in the guideline.

The guideline emphasises the need for shared decision making, putting patients at the centre of their care, and fostering a collaborative, supportive relationship between patients and healthcare professionals. It highlights the importance of healthcare professionals gaining an understanding of how a persons life affects their pain and how pain affects their life, including their work and leisure time, relationships with family and friends, and sleep.

The guideline recommends that a care and support plan should be developed based on the effects of pain on day-to-day activities, as well as a persons preferences, abilities and goals. It also highlights the importance of being honest with the person about the uncertainty of the prognosis.

The guideline makes recommendations for treatments that have been shown to be effective in managing chronic primary pain. These include exercise programmes and the psychological therapies CBT and acceptance and commitment therapy (ACT). Acupuncture is also recommended as an option.

People with chronic primary pain should not be started on commonly used drugs including paracetamol, non-steroidal anti-inflammatory drugs, benzodiazepines or opioids. This is because there is little or no evidence that they make any difference to peoples quality of life, pain or psychological distress, but they can cause harm, including possible addiction.

The guideline does recommend that an antidepressant can be considered for people aged 18years and over to manage chronic primary pain, after a full discussion of the benefits and harms. This is because the evidence shows antidepressants may help with quality of life, pain, sleep and psychological distress, even in the absence of a diagnosis of depression.

Dr Chrisp added: This guideline is very clear in highlighting that, based on the evidence, for most people its unlikely that any drug treatments for chronic primary pain, other than antidepressants, provide an adequate balance between any benefits they might provide and the risks associated with them.

But people shouldnt be worried that were asking them to simply stop taking their medicines without providing them with alternative, safer and more effective options. First and foremost, people who are taking medicines to treat their chronic primary pain which arent recommended in the guideline should ask their doctor to review their prescribing as part of shared decision making. This could involve agreeing a plan to carry on taking their medicines if they provide benefit at a safe dose and few harms, or support for them to reduce and stop the medicine if possible. When making shared decisions about whether to stop it's important that any problems associated with withdrawal are discussed and properly addressed.

Nick Kosky, a consultant psychiatrist at Dorset HealthCare NHS University Foundation Trust and chair of the guideline committee said: Understandably, people with chronic pain expect a clear diagnosis and effective treatment. But its complexity and the fact GPs and specialists alike find chronic pain very challenging to manage, means this is often not possible.

This guideline underlines the importance of appropriate assessment, careful drug choice, exercise programmes, psychological therapies, and consideration of acupuncture in improving the experience and outcomes of care for people with chronic pain.

Lucy Ryan, a patient representative on the guideline committee, said: This guideline will provide more consistency in treatment and support on the NHS for people experiencing chronic pain. I am pleased that it has highlighted the potential risks of some of the drugs used to treat chronic primary pain as I feel people are sometimes not made aware of these. I am also pleased that the guideline provides alternative treatment choices and that gaps in research have been identified. I hope that this will mean future guidelines will incorporate many more options for people managing chronic primary pain following further research. Everyone with chronic pain experiences pain differently so I feel the more options available to help people effectively manage their pain the better.

NICE is also producing guidelines on shared decision making and the safe prescribing and withdrawal management of medicines associated with dependence or withdrawal symptoms; these are expected to be published in June 2021 and November 2021 respectively.

See more here:

NICE recommends range of effective treatments for people with chronic primary pain and calls on healthcare professionals to recognise and treat a...

10th of April is celebrated as World Homeopathy Day to make the immense contribution of homeopathy to medicine, all around the world.

This day is observed on the birth anniversary of the founder of homeopathy, Dr Christian Friedrich Samuel Hahnemann who was a German-born in Paris on April 10, 1755.

Dr Hahnemann, a distinguished scientist and scholar discovered the way to heal through the use of homeopathyand his discovery, as well as methods, continue to serve humanity as a plausible complementary or alternative medicine.

As a complementary or alternative medicine, homeopathy is different from treatments that are part of conventional western medicine in many ways. A central principle of the treatment is that like cures like that a substance that causes certain symptoms can also help to remove it.

Just like many other branches of medicine, homeopathy has faced criticism in the past and continues to face the same today, however, its usage across the world is growing with prominent figures such as Queen Elizabeth II and her successor-Prince Charles being users and benefactors of this form of alternative medicine.

In 2007, Prince Charles wrote to the then-health secretary of the UK-Alan Johnson complaining that people were suffering unnecessarily as a result of the ministers anti-homeopathy campaign. In his letter, Charles stated, inter lia, that homeopathy offers an holistic, patient-centred, low-risk, low-cost, low-tech approach and that for all these reasons it must surely make abundant sense to safeguard the HHs [homeopathic hospitals] in the interests of the nations health.

In March 2020, it was reported that Queen Elizabeth, 94 years, continues to rely on homeopathy to keep her well during the coronavirus outbreak. The Queens mother, who lived to 101 was also said to be a fan of homeopathy.

If the royal family of Great Britain and over 100 million people in India solely depend on homeopathy for their medical care as well as over 100 million citizens of the European Union use homeopathic medicines, then surely its acceptance and growing popularity in Ghana was inevitable.

In celebrating homeopathy today, its journey and now prominence in Ghana is worthy of reminiscing. The early practitioners such as Dr Adu Boateng whose End Point Homeopathic Clinic is a front industry runner in Ghana faced several obstacles (from individual acceptance to regulatory issues) during the introduction of this form of alternative medicine to the mass market in Ghana over a decade ago.

Of course, there were people practising homeopathy in Ghana before I entered into practice over 10 years ago with End Point Homeopathic Clinic. However, these pioneers where practising a bit of everything in the sector of alternative medicine. Most of them had herbal medicine as their main area but delved into homeopathy too, Dr Adu Boateng in an interview stated.

He continued: It was a relentless struggle those days and it seems because a sole homeopathic practice was not in existence, the necessary regulatory framework was not developedso all these had to come into force gradually and instituted by the government for us to get to where we are today as a country that has somewhat widely accepted homeopathy.

With 5 branches across Ghana, Dr Adu Boateng and his End Point Homeopathy Clinic have successfully trained several homeopaths who have also established their clinics in Ghanafurthering his ultimate desire to bring homeopathy to the front doors of millions of Ghanaians.

End Point Homeopathy Clinic

Commenting on the growth and acceptance of homeopathy and the future of alternative medicine in Ghana, Dr Adu Boateng stated that it is refreshing to see more practitioners of homeopathy providing quality healthcare services in Ghanabut what is even more gratifying is the fact that treatments are working and more people are relying and trusting this form of alternative medicine.

However, he cautioned the general public against patronizing the practices of non-quality and unqualified practitionerssaying, there are a few people who as would be expected of any industry are doing anything and calling it homeopathy.

When it comes to a persons health, it cannot be played with, therefore, Ghanaians should make sure that they are only using well established and trustworthy homeopathic clinics to ensure that they receive the deserving healthcare, Dr Boateng said.

In celebrating this years World Homeopathy Day, End Point Homeopathy Clinic is offering free prostate screening for menand free fertility testing for women at all its branches across Ghana for the month of April.

Source: Ghanacelebrities.com

Featured Video

Read more here:

World Homeopathy Day: Celebrating The Leading Fathers Of Homeopathy In Ghana - Peace FM Online

The MHRA is committed to speeding up access to innovative new medicines for patients. The Early Access to Medicines Scheme (EAMS) gives patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need. The scheme has remained fully operational throughout the coronavirus (COVID-19) pandemic, ensuring that patients with serious conditions can still be offered new treatment options for their conditions.

As an example, the MHRA issued a positive scientific opinion for Roches atezolizumab (Tecentriq) in a new combination regimen for patients with unresectable hepatocellular carcinoma (HCC) in June 2020. Atezolizumab is a monoclonal antibody that directly binds programmed death-ligand 1 (PD-L1). PD-L1 may be expressed on tumour cells and/or tumour-infiltrating-immune cells and can contribute to the inhibition of the anti-tumour immune response in the tumour microenvironment.

Through EAMS, MHRA has been able to work with Roche since 2017 to ensure that over 600 UK patients with limited treatment options, have been among the first in the world to benefit from 8 breakthrough treatments prior to licence. This has paved the way for accelerated routine access in the NHS. To date, this working collaboration between MHRA and Roche has represented roughly a quarter of all EAMS run in the UK, including patients benefiting from receiving Tecentriq in five new cancer indications.

Cases of primary liver cancer are rising in the UK. HCC is the most common form of primary liver cancer and tends to be diagnosed at an advanced stage, often in cirrhotic livers, when very limited treatment options are available. For these patients, there is a high unmet need for alternative treatment options as their prognosis is poor, with rapid progression and short overall survival.

Roche benefitted from the MHRA validating the evidence generated at an early stage during the first step of the EAMS, the PIM (Promising Innovative Medicine) designation. The PIM designation gave an early indication from the MHRA that atezolizumab in combination with bevacizumab, was a potential candidate for EAMS. This enhanced opportunities for Roche to work with other stakeholders in the UK around patient access. Subsequently, Roche presented their positive Phase III clinical data at a pre-submission meeting with MHRA. This provided the company with an opportunity to discuss the dossier of evidence and consider data collection aspects with the MHRA in advance of a formal application. At this point, the MHRA recommended Roche submit an application for step II of EAMS, the Scientific Opinion (SO). During the SO assessment, the MHRA fully assessed the data generated for atezolizumab to ensure that the EAMS criteria were met and the benefits outweighed the risks. A resultant positive SO was issued.

There often is a time period between granting of a marketing authorisation (when EAMS closes) and NICE reimbursement, during which new patients may be unable to access the innovative medicine. Following a partnership between Roche, NHS England and NHS Improvement and the MHRA, the first Post-EAMS pilot was created to enable new patients to gain access to atezolizumab and bevacizumab during this time period.

During the EAMS period, 63 patients with HCC were able to access atezolizumab (in combination with bevacizumab) after discussions with their doctor. Submission through EAMS accelerated patient access to the treatment by around 4 months.

The Post-EAMS pilot has enabled Trusts in England to order medicine for patients using the same processes that were used for EAMS, saving capacity and NHS resources. During the relatively short duration of this pilot, 13 more eligible HCC patients were able to access treatment with atezolizumab and bevacizumab.

Tecentriq, in combination with Avastin, is now the first cancer immunotherapy treatment recommended by NICE for HCC.

Milestone dates include:

The IMbrave150 trial was published in New England Journal of Medicine in May 2020 and established the superiority of atezolizumab and bevacizumab for advanced hepatocellular carcinoma compared to the existing standard of care. The Roche EAMS allowed us to offer this new standard of care to our patients within 8 weeks of the publication and the Post-EAMS pilot facilitated seamless transition to NHS provision.

The close collaboration between Roche and regulators has enabled the translation of research, partly conducted in the UK, into patient benefit with minimal delay and great efficiency.

Roches EAMS journey with atezolizumab (in combination with bevacizumab) is a good example of the NHS continuing to support patient access to innovative treatment throughout the coronavirus pandemic.

Thanks to the partnership working between Roche, NHS England and NHS Improvement, and the MHRA, access continued through the Post-EAMS pilot, allowing clinicians to choose this treatment to support their patients and demonstrating the potential for this collaborative approach to be expanded for an enhanced EAMS programme.

Raising awareness of EAMS, especially during the coronavirus pandemic is important to ensure patients with high unmet medical needs such as these HCC patients, do not miss out on potentially life-changing new treatments.

The MHRA and Roche have been steadfast in their commitment to the assessment of the EAMS Scientific Opinion, ensuring no delay to early access for HCC patients even amidst all the challenges presented by the pandemic.

The addition of the Post-EAMS pilot to EAMS demonstrates that UK health agencies in collaboration with industry partners may be able to feasibly offer a more streamlined process to enable equitable early access to innovative treatments in the UK. Learnings from this pilot will help to refine the process for future EAMS programs.

EAMS aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need. Visit EAMS to find out more.

You may also find help to expedite your medicines to patients by visiting the MHRA Innovation Office which provides free and confidential expert regulatory information and advice. Find out more about how the innovation office has helped support innovation; read our case studies.

Read more:

Early Access continues during the coronavirus (COVID-19) pandemic - GOV.UK

Alternative therapy subsets such as gene-based solutions have been gathering momentum at a remarkable pace in recent times.

The potential applications of genome engineering are poised to have a deeply significant impact on the future of medical advancements and healthcare as we know it. Initially facing a barrage of acceptance challenges in the form of approval from government bodies and other authorities, gene therapy has evolved over the years to include the potential to prevent hereditary diseases such as hemophilia and cystic fibrosis, as well as presenting a possible cure for cancer, AIDS and heart disease.

CRISPR-based diagnostics in particular, have evolved at a substantial pace over the last couple of years. In 2020, the Covid-19 situation only accelerated the advent of these gene editing tools and magnified their role within the industry.

Many researchers moved to study the virus and brought gene editing and sequencing technologies to the forefront to meet the need of the hour.

CRISPR-based technology also served the urgent need for faster and better testing diagnostics through gene detection. It was used successfully to develop rapid Covid-19 testing and attained its first US Food and Drug Administration (FDA) approval. CRISPR technology further helped the shift from physical facilities to point-of-care settings including off-the-shelf tests or pop-up testing centres.

Researchers and scientists are also turning to CRISPRs applications as a possible therapeutic option to destroy the Covid-19 genomic RNA and stop viral replication. In March, Belgian researchers identified host factors necessary for a Covid-19 infection by performing genome-wide genetic screens. This breakthrough could allow the use of such factors in developing drugs to treat Covid-19 or even potential future outbreaks of similar coronaviruses.

Evidently, the current pandemic has accelerated development of CRISPR and other gene-based diagnostics. The need for rapid and scalable solutions is fueling growth in genome-based diagnostics, thus opening up a barrage of new avenues for gene therapy to achieve mainstream status. Fittingly in 2021, the global CRISPR gene editing market is forecast to grow substantially over the next decade, at a staggering 26.86 per cent CAGR from its estimated valuation of $846.2m in 2019, to reach $10.8bn by 2030.

The market for alternative therapies, such as gene-based solutions has also garnered investor interest on the back of advancements witnessed in recent months and years. US-based Clear Labs raised funding to the tune of $18m in May 2020 over its prospects following its 2019 Oxford Nanopore Technologies distribution agreement.

Equity markets have also acknowledged the vast potential in this relatively under-tapped and nascent segment, even as companies employed in the manufacturing, research, development and provision of gene-based therapeutics and solutions are witnessing rising active investor interest. The advent of a market for such powerful new bioengineering tools is emphasised in the uptick of several standout companies.

For instance, CRISPR Therapeutics, which develops gene-based medicines for serious diseases through its revolutionary CRISPR/Cas9 platform, offers therapeutic programmes across a wide range of rare diseases, oncology, hemoglobinopathies and regenerative medicine.

With notable prior successes in treating hereditary retinal and blood disorders with gene therapy, CRISPRs efforts to expand has now driven collaborations with leading firms such as Vertex Pharmaceuticals and Bayer, and in 2020, sent its stock up by over 150 per cent.

Genetic testing company Fulgent Genetica is another strong player, offering 18,000 single-gene tests, over 800 tests for rare diseases, as well as genome sequencing. In 2020, its stock jumped a remarkable 304 per cent on the back of a surge in testing volumes post Covid-19, with the stock price multiplying more than 9x since the start of 2020 (as of March 17). The companys recent Q4 earnings also beat estimates, with strong Y-o-Y improvements in both top and bottom-line figures (+3,400 per cent revenue growth), and 2021 guidance projecting 90 per cent revenue growth.

The $19bn biotech firm 10x Genomics is broadly engaged in gene sequencing, and deals in instruments, consumables and software for analysing biological systems. Its Q4 earnings beat estimates and showed a 49 per cent Y-o-Y growth in revenue, largely from higher sales of consumables used with its genomic analysis instruments. Its strong fundamentals pushed its stock up by roughly 86 per cent in 2020, and its expansion plans are likely to boost the companys prospects over the coming year.

Twist Bioscience Corp is yet another fast-growing synthetic biology and genomics company whose pioneering DNA synthesis platform is enabling manufacturing of a wide array of products such as synthetic genes and next-generation sequencing (NGS) preparation tools. The companys plans to highlight genotyping by sequencing and its new NGS Methylation Detection system, together with its exploring of long-term opportunities in DNA digital data storage and biologics drug discovery, are sparking keen investor interest in its growth prospects, marking its stock a buy by multiple market analysts, even as it recorded a staggering 590 per cent stock surge since 2020 (as of March 17).

Apart from genome-based therapeutics, other alternative therapies are also emerging as niche segments.

Technological advances in medicine are now going beyond all previous norms, and powerful new technologies are emerging with potential to shake up medical sciences.

Researchers across the world are continually seeking cures for a host of genetic, mutative, chronic, hereditary and mental diseases, through alternative therapies.

For example, gene therapies are finding uses to formulate products such as industrial materials and biofuels, apart from their medical applications. Investment into such domains is likely to pay off in the long term, as R&D begets medical discoveries, which offer new ways to optimise such tools for human benefit.

The clinical market of the future will be driven by next-generation gene sequencing, robotic automation and more, with investment fostering continuous development and evolution.

Disclaimer:This column is purely for academic and educational purposes. Nothing mentioned here should be taken as solicitation to trade or a recommendation of a specific trade. The author has direct exposure in some of the recommended stocks.

Go here to read the rest:

Phi Trends: Healthy growth for alternative therapies - Gulf Business